 |
|
|
|
|
|
Medical Affairs Bulletins |
|
|
|
|
|
|
|
|
|
|
|
|
|
| The following literature is available for use by lab and medical professionals.
Just click the thumbnail below to view the full-size image in pdf format. The
pdf version can be saved or printed as needed.
|
Friedewald Estimated LDL Cholesterol (LDLc) Results in Discordance and Misclassification of Patient Risk Compared to VAP Lipid Panel Directly Measured LDLc. Published by the Journal of the American College of Cardiology; April 2013.
|
Triglyceride-Rich Remnant Lipoprotein Cholesterol Predicts Acute Myocardial Infarction in African Americans: The Jackson Heart Study. Summary of an Oral Contribution using the VAP® Lipid Panel. Presented at American College of Cardiology Scientific Sessions; March 2013
|
Impact of Lipoprotein Remnants on 12 Year Risk for CHD in the Framingham Offspring Population. Summary of a Poster Abstract using the VAP® Lipid Panel. Presented at the American College of Cardiology Scientific Sessions; March 2013
|
Impact of HDLc And Its Subfractions On Risk For CHD In The Framingham Offspring Population. Summary of a Poster Abstract using the VAP® Lipid Panel. Presented at American College of Cardiology Scientific Sessions; March 2013
|
HDL Subclasses are Not All Created Equal: Association of HDL Subclasses and Incident Cardiovascular Events in African Americans from the Jackson Heart Study. Study presented at American Heart Association Scientific Sessions; November 2012
|
Impact of LDL Patterns on Risk for CHD in the Framingham Offspring Population. Study presented at American Heart Association Scientific Sessions; November 2012
|
HDL Cholesterol Subclasses and Mortality after Acute Myocardial Infarction: The TRIUMPH Prospective Multi-Center Registry. Study presented at American Heart Association Scientific Sessions; November 2012
|
Lipoprotein Effects of Exenatide in Diabetic Subjects with Elevated Pretreatment Levels of Serum Lipoprotein(a) Cholesterol: A Post Hoc Analysis of DURATION-1. Study presented at National Lipid Association; June 2012
|
Treatment with Exenatide Associated with Favorable Lipid and Lipid Subclass Changes in Patient Values. Study presented at National Lipid Association; June 2012
|
Reduction In Estimated 10-Year Coronary Heart Disease Risk Using Reynolds Risk Score. Study presented at National Lipid Association; June 2012
|
Underestimation of LDL-C by Friedewald - Study presented at American College of Cardiology; March 2012
|
JCL – Niacin Simva VAP Study; March 2012
|
The role of Lp(a) - Understanding Lp(a) Cholesterol and Lp(a) Protein Mass; February 2012
|
CIMT Study – Vascular Health and Risk Management; February 2012
|
WellMed Study – Population Health Management; January 2012
|
|
|
"Using the detailed lipid profiles in the VAP Cholesterol Test, we can identify atherosclerosis risk that goes far beyond the capabilities of the standard lipid profile. A cholesterol test which identifies the complete lipid picture can complement lipid risk identification and targeted lipid treatment in our clinical practices."
- Michael E. Cobble, M.D. AAFP, FNLA, Board Certified Clinical Lipidologist (NLA), Certified HTN Specialist (ASH), Masters in Psychopharmacology, Director Private Practice Canyons Medical Center, Adjunct Faculty Univ. Utah School of Medicine |
|
|
The VAP Test
Medical Affairs
